Nitric Oxide Nasal Spray (Nons) developed by SaNOtize, a Canada based company, has been claimed to be effective in treatment of Covid. A self-administered nasal spray application is found to have reduced Covid viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours.
The results of clinical trials were revealed by Biotech Company SaNOtize, St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK.
According to a report, in a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of Covid-19, SaNOtize’s early treatment for Covid significantly reduced the level of SARS-CoV-2, including in patients with high viral loads.
As per the findings, the average viral load reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. Within 72 hours, the viral load dropped by more than 99%.
It is claimed that the majority of these patients had been infected with the UK variant, which is considered a variant of concern. There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials.
Dr. Stephen Winchester, Consultant Medical Virologist and Chief Investigator of this NHS Clinical Trial, said, “I expect this to be a major advance in the global battle against the devastating human impacts of the Covid-19 pandemic.”
He added that this simple portable nasal spray could be highly effective in the treatment of Covid-19 and reducing onward transmission.
“Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of Covid, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. Simply stated, I think this could be revolutionary,” explained Dr Winchester.
SaNOtize has said that this spray is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on Covid, the virus that causes Covid-19.
“The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies,” said the company.
With encouraging results, the company is applying to regulatory authorities in the UK and Canada for Emergency Use authorization.
“Now that Nons has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality, and prevent future outbreaks of COVID-19 and its variants,” said Dr. Gilly Regev, CEO and co-founder of SaNOtize.
“The human toll of this disease cannot be expressed simply in numbers, and each day compounds the frustration, fear and loss suffered by millions around the world. Combined with the roll-out of vaccines, Nons can help get the world back on its feet,” Dr. Gilly Regev.